Clofazimine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Clofazimine" in English language version.

refsWebsite

Global rank English rank

25nih.gov

4^th place

16doi.org

2^nd place

6semanticscholar.org

11^th place

8^th place

5harvard.edu

18^th place

17^th place

4web.archive.org

1^st place

2handle.net

102^nd place

76^th place

2books.google.com

3^rd place

1drugs.com

399^th place

333^rd place

1asm.org

3,555^th place

low place

1centerwatch.com

low place

1medscape.com

719^th place

636^th place

asm.org

aac.asm.org

"Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin".

books.google.com

Greenwood D (2008). Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. OUP Oxford. p. 200. ISBN 9780199534845. By 1954 related molecules known as iminophenazines were being investigated... one of the first ones to be made, originally given the laboratory code B663 ... B663—subsequently called clofazimine
Brown S (1998). Psychiatric Side Effects of Prescription and Over-the-counter Medications: Recognition and Management. American Psychiatric Pub. ISBN 9780880488686. Archived from the original on 2016-03-05.

centerwatch.com

"Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) | Clinical Research Trial Listing ( Mycobacterium avium Complex | MAC Infection (Mycobacterium Avium Complex) | Mycobacterium avium-intracellulare Infection ) ( NCT02968212 )". Archived from the original on 2022-09-13. Retrieved 2020-11-11.

doi.org

Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA (May 2016). "Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin". Chest. 149 (5): 1285–1293. doi:10.1378/chest.15-0543. PMID 26513209.
Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, et al. (May 2021). "Clofazimine broadly inhibits coronaviruses including SARS-CoV-2". Nature. 593 (7859): 418–423. Bibcode:2021Natur.593..418Y. doi:10.1038/s41586-021-03431-4. PMC 7553155. PMID 33727703. S2CID 232262689.
Arbiser JL, Moschella SL (February 1995). "Clofazimine: a review of its medical uses and mechanisms of action". Journal of the American Academy of Dermatology. 32 (2 Pt 1): 241–247. doi:10.1016/0190-9622(95)90134-5. PMID 7829710.
Kagan VE (1989). "Tocopherol stabilizes membrane against phospholipase A, free fatty acids, and lysophospholipids". Annals of the New York Academy of Sciences. 570 (1): 121–135. Bibcode:1989NYASA.570..121K. doi:10.1111/j.1749-6632.1989.tb14913.x. PMID 2698101. S2CID 44638207.
Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. (2011). "Identification of novel functional inhibitors of acid sphingomyelinase". PLOS ONE. 6 (8): e23852. Bibcode:2011PLoSO...623852K. doi:10.1371/journal.pone.0023852. PMC 3166082. PMID 21909365.
Baik J, Rosania GR (October 2011). "Molecular imaging of intracellular drug-membrane aggregate formation". Molecular Pharmaceutics. 8 (5): 1742–1749. doi:10.1021/mp200101b. PMC 3185106. PMID 21800872.
Gatner EM, Anderson R, van Remsburg CE, Imkamp FM (June 1982). "The in vitro and in vivo effects of clofazimine on the motility of neutrophils and transformation of lymphocytes from normal individuals". Leprosy Review. 53 (2): 85–90. doi:10.5935/0305-7518.19820010. PMID 7098757. S2CID 46460241.
van Rensburg CE, Gatner EM, Imkamp FM, Anderson R (May 1982). "Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy". Antimicrobial Agents and Chemotherapy. 21 (5): 693–697. doi:10.1128/aac.21.5.693. PMC 181995. PMID 7049077.
Kashyap A, Sehgal VN, Sahu A, Saha K (February 1992). "Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes in vitro". International Journal of Immunopharmacology. 14 (2): 269–273. doi:10.1016/0192-0561(92)90039-N. PMID 1624226.
Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, et al. (Dec 2008). "Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes". PLOS ONE. 3 (12): e4009. Bibcode:2008PLoSO...3.4009R. doi:10.1371/journal.pone.0004009. PMC 2602975. PMID 19104661.
Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. (November 2006). "Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17414–17419. Bibcode:2006PNAS..10317414B. doi:10.1073/pnas.0605136103. PMC 1859943. PMID 17088564.
Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG (June 2003). "The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS". The Journal of Clinical Investigation. 111 (11): 1703–1713. doi:10.1172/JCI16921. PMC 156104. PMID 12782673.
Mackey JP, Barnes J (July 1974). "Clofazimine in the treatment of discoid lupus erythematosus". The British Journal of Dermatology. 91 (1): 93–96. doi:10.1111/j.1365-2133.1974.tb06723.x. PMID 4851057. S2CID 43528153.
Jakes JT, Dubois EL, Quismorio FP (November 1982). "Antileprosy drugs and lupus erythematosus". Annals of Internal Medicine. 97 (5): 788. doi:10.7326/0003-4819-97-5-788_2. PMID 7137755.
Chuaprapaisilp T, Piamphongsant T (September 1978). "Treatment of pustular psoriasis with clofazimine". The British Journal of Dermatology. 99 (3): 303–305. doi:10.1111/j.1365-2133.1978.tb02001.x. PMID 708598. S2CID 36255192.
Podmore P, Burrows D (March 1986). "Clofazimine--an effective treatment for Melkersson-Rosenthal syndrome or Miescher's cheilitis". Clinical and Experimental Dermatology. 11 (2): 173–178. doi:10.1111/j.1365-2230.1986.tb00443.x. PMID 3720016. S2CID 631224.

drugs.com

"Clofazimine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.

handle.net

hdl.handle.net

World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 132. hdl:10665/44053. ISBN 9789241547659.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

ui.adsabs.harvard.edu

Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, et al. (May 2021). "Clofazimine broadly inhibits coronaviruses including SARS-CoV-2". Nature. 593 (7859): 418–423. Bibcode:2021Natur.593..418Y. doi:10.1038/s41586-021-03431-4. PMC 7553155. PMID 33727703. S2CID 232262689.
Kagan VE (1989). "Tocopherol stabilizes membrane against phospholipase A, free fatty acids, and lysophospholipids". Annals of the New York Academy of Sciences. 570 (1): 121–135. Bibcode:1989NYASA.570..121K. doi:10.1111/j.1749-6632.1989.tb14913.x. PMID 2698101. S2CID 44638207.
Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. (2011). "Identification of novel functional inhibitors of acid sphingomyelinase". PLOS ONE. 6 (8): e23852. Bibcode:2011PLoSO...623852K. doi:10.1371/journal.pone.0023852. PMC 3166082. PMID 21909365.
Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, et al. (Dec 2008). "Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes". PLOS ONE. 3 (12): e4009. Bibcode:2008PLoSO...3.4009R. doi:10.1371/journal.pone.0004009. PMC 2602975. PMID 19104661.
Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. (November 2006). "Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17414–17419. Bibcode:2006PNAS..10317414B. doi:10.1073/pnas.0605136103. PMC 1859943. PMID 17088564.

medscape.com

reference.medscape.com

"Lamprene (clofazimine) dosing, indications, interactions, adverse effects, and more". Archived from the original on 2014-07-09. Retrieved 2014-06-13.

nih.gov

pubmed.ncbi.nlm.nih.gov

Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA (May 2016). "Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin". Chest. 149 (5): 1285–1293. doi:10.1378/chest.15-0543. PMID 26513209.
Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, et al. (May 2021). "Clofazimine broadly inhibits coronaviruses including SARS-CoV-2". Nature. 593 (7859): 418–423. Bibcode:2021Natur.593..418Y. doi:10.1038/s41586-021-03431-4. PMC 7553155. PMID 33727703. S2CID 232262689.
Arbiser JL, Moschella SL (February 1995). "Clofazimine: a review of its medical uses and mechanisms of action". Journal of the American Academy of Dermatology. 32 (2 Pt 1): 241–247. doi:10.1016/0190-9622(95)90134-5. PMID 7829710.
Morrison NE, Marley GM (1976). "The mode of action of clofazimine DNA binding studies". International Journal of Leprosy and Other Mycobacterial Diseases. 44 (1–2): 133–134. PMID 945233.
Kagan VE (1989). "Tocopherol stabilizes membrane against phospholipase A, free fatty acids, and lysophospholipids". Annals of the New York Academy of Sciences. 570 (1): 121–135. Bibcode:1989NYASA.570..121K. doi:10.1111/j.1749-6632.1989.tb14913.x. PMID 2698101. S2CID 44638207.
Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. (2011). "Identification of novel functional inhibitors of acid sphingomyelinase". PLOS ONE. 6 (8): e23852. Bibcode:2011PLoSO...623852K. doi:10.1371/journal.pone.0023852. PMC 3166082. PMID 21909365.
Baik J, Rosania GR (October 2011). "Molecular imaging of intracellular drug-membrane aggregate formation". Molecular Pharmaceutics. 8 (5): 1742–1749. doi:10.1021/mp200101b. PMC 3185106. PMID 21800872.
Conalty ML, Barry VC, Jina A (Apr 1971). "The antileprosy agent B.663 (Clofazimine) and the reticuloendothelial system". International Journal of Leprosy and Other Mycobacterial Diseases. 39 (2): 479–492. PMID 4948088.
Gatner EM, Anderson R, van Remsburg CE, Imkamp FM (June 1982). "The in vitro and in vivo effects of clofazimine on the motility of neutrophils and transformation of lymphocytes from normal individuals". Leprosy Review. 53 (2): 85–90. doi:10.5935/0305-7518.19820010. PMID 7098757. S2CID 46460241.
van Rensburg CE, Gatner EM, Imkamp FM, Anderson R (May 1982). "Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy". Antimicrobial Agents and Chemotherapy. 21 (5): 693–697. doi:10.1128/aac.21.5.693. PMC 181995. PMID 7049077.
Kashyap A, Sehgal VN, Sahu A, Saha K (February 1992). "Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes in vitro". International Journal of Immunopharmacology. 14 (2): 269–273. doi:10.1016/0192-0561(92)90039-N. PMID 1624226.
Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, et al. (Dec 2008). "Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes". PLOS ONE. 3 (12): e4009. Bibcode:2008PLoSO...3.4009R. doi:10.1371/journal.pone.0004009. PMC 2602975. PMID 19104661.
Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. (November 2006). "Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17414–17419. Bibcode:2006PNAS..10317414B. doi:10.1073/pnas.0605136103. PMC 1859943. PMID 17088564.
Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG (June 2003). "The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS". The Journal of Clinical Investigation. 111 (11): 1703–1713. doi:10.1172/JCI16921. PMC 156104. PMID 12782673.
Mackey JP, Barnes J (July 1974). "Clofazimine in the treatment of discoid lupus erythematosus". The British Journal of Dermatology. 91 (1): 93–96. doi:10.1111/j.1365-2133.1974.tb06723.x. PMID 4851057. S2CID 43528153.
Jakes JT, Dubois EL, Quismorio FP (November 1982). "Antileprosy drugs and lupus erythematosus". Annals of Internal Medicine. 97 (5): 788. doi:10.7326/0003-4819-97-5-788_2. PMID 7137755.
Chuaprapaisilp T, Piamphongsant T (September 1978). "Treatment of pustular psoriasis with clofazimine". The British Journal of Dermatology. 99 (3): 303–305. doi:10.1111/j.1365-2133.1978.tb02001.x. PMID 708598. S2CID 36255192.
Podmore P, Burrows D (March 1986). "Clofazimine--an effective treatment for Melkersson-Rosenthal syndrome or Miescher's cheilitis". Clinical and Experimental Dermatology. 11 (2): 173–178. doi:10.1111/j.1365-2230.1986.tb00443.x. PMID 3720016. S2CID 631224.

ncbi.nlm.nih.gov

Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, et al. (May 2021). "Clofazimine broadly inhibits coronaviruses including SARS-CoV-2". Nature. 593 (7859): 418–423. Bibcode:2021Natur.593..418Y. doi:10.1038/s41586-021-03431-4. PMC 7553155. PMID 33727703. S2CID 232262689.
Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. (2011). "Identification of novel functional inhibitors of acid sphingomyelinase". PLOS ONE. 6 (8): e23852. Bibcode:2011PLoSO...623852K. doi:10.1371/journal.pone.0023852. PMC 3166082. PMID 21909365.
Baik J, Rosania GR (October 2011). "Molecular imaging of intracellular drug-membrane aggregate formation". Molecular Pharmaceutics. 8 (5): 1742–1749. doi:10.1021/mp200101b. PMC 3185106. PMID 21800872.
van Rensburg CE, Gatner EM, Imkamp FM, Anderson R (May 1982). "Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy". Antimicrobial Agents and Chemotherapy. 21 (5): 693–697. doi:10.1128/aac.21.5.693. PMC 181995. PMID 7049077.
Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, et al. (Dec 2008). "Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes". PLOS ONE. 3 (12): e4009. Bibcode:2008PLoSO...3.4009R. doi:10.1371/journal.pone.0004009. PMC 2602975. PMID 19104661.
Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. (November 2006). "Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17414–17419. Bibcode:2006PNAS..10317414B. doi:10.1073/pnas.0605136103. PMC 1859943. PMID 17088564.
Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG (June 2003). "The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS". The Journal of Clinical Investigation. 111 (11): 1703–1713. doi:10.1172/JCI16921. PMC 156104. PMID 12782673.

semanticscholar.org

api.semanticscholar.org

Yuan S, Yin X, Meng X, Chan JF, Ye ZW, Riva L, et al. (May 2021). "Clofazimine broadly inhibits coronaviruses including SARS-CoV-2". Nature. 593 (7859): 418–423. Bibcode:2021Natur.593..418Y. doi:10.1038/s41586-021-03431-4. PMC 7553155. PMID 33727703. S2CID 232262689.
Kagan VE (1989). "Tocopherol stabilizes membrane against phospholipase A, free fatty acids, and lysophospholipids". Annals of the New York Academy of Sciences. 570 (1): 121–135. Bibcode:1989NYASA.570..121K. doi:10.1111/j.1749-6632.1989.tb14913.x. PMID 2698101. S2CID 44638207.
Gatner EM, Anderson R, van Remsburg CE, Imkamp FM (June 1982). "The in vitro and in vivo effects of clofazimine on the motility of neutrophils and transformation of lymphocytes from normal individuals". Leprosy Review. 53 (2): 85–90. doi:10.5935/0305-7518.19820010. PMID 7098757. S2CID 46460241.
Mackey JP, Barnes J (July 1974). "Clofazimine in the treatment of discoid lupus erythematosus". The British Journal of Dermatology. 91 (1): 93–96. doi:10.1111/j.1365-2133.1974.tb06723.x. PMID 4851057. S2CID 43528153.
Chuaprapaisilp T, Piamphongsant T (September 1978). "Treatment of pustular psoriasis with clofazimine". The British Journal of Dermatology. 99 (3): 303–305. doi:10.1111/j.1365-2133.1978.tb02001.x. PMID 708598. S2CID 36255192.
Podmore P, Burrows D (March 1986). "Clofazimine--an effective treatment for Melkersson-Rosenthal syndrome or Miescher's cheilitis". Clinical and Experimental Dermatology. 11 (2): 173–178. doi:10.1111/j.1365-2230.1986.tb00443.x. PMID 3720016. S2CID 631224.

web.archive.org

"Clofazimine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
"Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) | Clinical Research Trial Listing ( Mycobacterium avium Complex | MAC Infection (Mycobacterium Avium Complex) | Mycobacterium avium-intracellulare Infection ) ( NCT02968212 )". Archived from the original on 2022-09-13. Retrieved 2020-11-11.
Brown S (1998). Psychiatric Side Effects of Prescription and Over-the-counter Medications: Recognition and Management. American Psychiatric Pub. ISBN 9780880488686. Archived from the original on 2016-03-05.
"Lamprene (clofazimine) dosing, indications, interactions, adverse effects, and more". Archived from the original on 2014-07-09. Retrieved 2014-06-13.